Apelin reduces harmful fat byproducts in muscles, which helps muscles take up more glucose in response to insulin.
Scientific Claim
Chronic apelin treatment (0.1 μmol/kg/day intraperitoneally for 4 weeks) in high-fat diet-induced insulin-resistant mice is associated with reduced long-chain acylcarnitine levels (C16:1 and C18:1 species) in skeletal muscle (n=7 PBS vs n=8 apelin, P ≤ 0.05), which correlates with improved insulin-stimulated glucose uptake (n=6 apelin vs n=7 PBS, P ≤ 0.05).
Original Statement
“Long-chain acylcarnitines were elevated in homogenates of soleus muscle from HFD insulin-resistant mice compared with ND control mice (Fig. 6A). It is interesting that in HFD apelin-treated mice, acylcarnitine levels, especially C16:1 and C18:1 species, were reduced when compared with HFD PBS-treated mice. ... insulin-stimulated glucose uptake was significantly increased in apelin-treated mice muscle compared with PBS-treated mice (Fig. 6B).”
Evidence Quality Assessment
Claim Status
appropriately stated
Study Design Support
Design supports claim
Appropriate Language Strength
association
Can only show association/correlation
Assessment Explanation
The claim uses 'associated with' which correctly reflects the associative nature of the study design, avoiding causal language.
Evidence from Studies
Supporting (1)
Apelin Treatment Increases Complete Fatty Acid Oxidation, Mitochondrial Oxidative Capacity, and Biogenesis in Muscle of Insulin-Resistant Mice